ReviewDiabetes & metabolic syndrome
Interactions between antihyperglycemic drugs and the renin-angiotensin system: Putative roles in COVID-19. A mini-review.
Review in Diabetes & metabolic syndrome. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 24 citations in OpenAlex.
- Targeting of neuroinflammation by glibenclamide in Covid-19: old weapon from arsenal.Inflammopharmacology · 2023Review
- Molecular and cellular mechanisms involved in tissue-specific metabolic modulation by SARS-CoV-2.Frontiers in microbiology · 2022Review
- COVID-19 and renin angiotensin aldosterone system: Pathogenesis and therapy.Health science reports · 2021Review
- The therapeutic potential of the novel angiotensin-converting enzyme 2 in the treatment of coronavirus disease-19.Veterinary world · 2021Review
- Biologia Futura: is ADAM 17 the reason for COVID-19 susceptibility in hyperglycemic and diabetic patients?Biologia futura · 2021Review
- Protecting older patients with cardiovascular diseases from COVID-19 complications using current medications.European geriatric medicine · 2021Review
- Network pharmacology, molecular docking integrated surface plasmon resonance technology reveals the mechanism of Toujie Quwen Granules against coronavirus disease 2019 pneumonia.Phytomedicine : international journal of phytotherapy and phytopharmacology · 2021Article
- Should ACE2 be given a chance in COVID-19 therapeutics: A semi-systematic review of strategies enhancing ACE2.European journal of pharmacology · 2020Review
- A protein interaction map identifies existing drugs targeting SARS-CoV-2.BMC pharmacology & toxicology · 2020Article
- COVID-KOP: Integrating Emerging COVID-19 Data with the ROBOKOP Database.ChemRxiv : the preprint server for chemistry · 2020Article
- The COVID-19 Pandemic during the Time of the Diabetes Pandemic: Likely Fraternal Twins?Pathogens (Basel, Switzerland) · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDiabetes mellitus is associated with a more severe course of coronavirus disease 2019 (COVID-19). The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) utilizes angiotensin-converting enzyme II (ACE2) receptor for host cell entry. We aimed to assess the interactions between antihyperglycemic drugs and the renin-angiotensin system (RAS) and their putative roles in COVID-19.
methodsA literature search was performed using Pubmed to review the interrelationships between hyperglycemia, RAS and COVID-19, and the effects of antihyperglycemic medications.
resultsThe RAS has an essential role in glucose homeostasis and may have a role in COVID-19-induced lung injury. Some antihyperglycemic medications modulate RAS and might hypothetically alleviate the deleterious effect of angiotensin II on lung injury. Furthermore, most antihyperglycemic medications showed anti-inflammatory effects in animal models of lung injury.
conclusionsSome antihyperglycemic medications might have protective effects against COVID-19-induced lung injury. Early insulin therapy seems very promising in alleviating lung injury.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.